AHK-Cu: The Hair-Growth Copper Peptide
Alanine-Histidine-Lysine + Cu(II). A narrow-spectrum copper peptide that targets dermal papilla cells, stimulates VEGF, and prolongs the anagen growth phase. Not the same as GHK-Cu.
How It Works
AHK-Cu stimulates Vascular Endothelial Growth Factor (VEGF) expression in dermal papilla cells, increasing peri-follicular angiogenesis. More blood vessels around the follicle = more nutrient and oxygen delivery during the growth phase.
Extends the anagen (active growth) phase of the hair cycle and delays the catagen transition. Pyo et al. 2007 documented sustained elongation of cultured human hair follicles over 7 days at nanomolar concentrations.
Increases proliferation of dermal papilla cells (DPCs) — the signal-sending fibroblast population at the base of each hair follicle that controls growth phase and follicle size.
Cu(II) is an essential cofactor for lysyl oxidase (collagen/elastin crosslinking) and for tyrosinase. The peptide chelate delivers copper to the follicle without the systemic load of free copper.
What the Data Shows
Key Takeaways
- AHK-Cu is a copper-chelating tripeptide (Ala-His-Lys + Cu²⁺) studied almost exclusively for hair-follicle biology — distinct from GHK-Cu, which is studied broadly for wound healing and skin remodeling.
- Mechanism is VEGF-mediated angiogenesis at the dermal papilla plus direct dermal papilla cell proliferation, prolonging the anagen growth phase.
- Pyo et al. 2007 (Biological & Pharmaceutical Bulletin) documented elongation of cultured human hair follicles within 7 days at nanomolar concentrations.
- Almost all commercial use is topical (0.01–0.05% in serums such as Tricomin, Folligen, and many Korean/Japanese hair products) — there are no human injectable AHK-Cu studies.
- Often combined with biotinyl-GHK, copper PCA, oligopeptide-2, and minoxidil in real-world stacks; the peptide complex formulations have the most evidence.
- Cu(II) is an obligate cofactor for lysyl oxidase (the enzyme that cross-links collagen and elastin) — part of the structural benefit at the follicle base.
- There are no large randomized controlled trials of AHK-Cu monotherapy in androgenetic alopecia — evidence is in vitro, ex vivo human follicle culture, rodent, and small open-label cosmetic studies.
- AHK-Cu is not FDA-approved for hair loss. Minoxidil and finasteride remain the only FDA-cleared treatments with Phase 3 efficacy data.
- Optimal concentration, vehicle, and dosing frequency for topical AHK-Cu have not been formally established by regulatory studies.
- Whether AHK-Cu adds clinically meaningful benefit on top of minoxidil + finasteride is not established — most "stack" claims are extrapolated from mechanism.
- Long-term (years) safety of daily topical use is not well-characterized in trials, though no major safety signals have emerged in cosmetic use over the past two decades.
- AHK-Cu does NOT inhibit 5α-reductase or block DHT — it works on follicle biology downstream of the androgen pathway, so it is mechanistically complementary to finasteride, not a substitute.
Frequently Asked Questions
What is AHK-Cu and how is it different from GHK-Cu?
AHK-Cu is Alanine-Histidine-Lysine bound to Cu(II); GHK-Cu is Glycine-Histidine-Lysine bound to Cu(II). The single amino-acid swap (Gly → Ala) shifts the biological target: GHK-Cu has broad activity across wound healing, anti-inflammatory pathways, and 4,000+ genes; AHK-Cu has been studied almost exclusively for hair-follicle biology, where it stimulates VEGF in dermal papilla cells and prolongs the anagen (growth) phase. Both share the copper-chelate backbone, but they are not interchangeable.
Does AHK-Cu actually regrow hair?
In vitro and ex vivo human follicle data show AHK-Cu lengthens follicles and prolongs the anagen phase at nanomolar concentrations (Pyo et al. 2007; Lee et al. 2007). Real-world cosmetic data is encouraging but small-scale and largely from peptide-complex formulations (Tricomin, Folligen) rather than AHK-Cu monotherapy. It is not FDA-approved for hair loss and has no Phase 3 trial data comparable to minoxidil or finasteride.
How is AHK-Cu used — topical or injection?
Topical only in any meaningful evidence base. Typical concentrations are 0.01–0.05% in a hair serum or scalp leave-in, applied 1–2× daily and reassessed at 3–6 months. There are no human safety or efficacy data for injectable AHK-Cu, and topical delivery puts the peptide where it is needed (the follicle) without systemic copper exposure.
Can I stack AHK-Cu with minoxidil and finasteride?
Mechanistically yes — AHK-Cu acts on follicle biology (VEGF, dermal papilla, anagen length), minoxidil opens K⁺ channels and prolongs anagen, finasteride lowers DHT. The three target different parts of the pathway, so they are not redundant. Whether the AHK-Cu addition produces a clinically meaningful incremental benefit on top of the FDA-approved drugs has not been formally tested in a randomized trial.
Is AHK-Cu safe?
Two decades of topical cosmetic use has produced no major safety signals. Mild scalp irritation is the most common reported issue. Avoid applying strong topical antioxidants (high-dose vitamin C) at the same time as the copper peptide, since the redox interaction can degrade the chelate. Do not use on broken or inflamed scalp. There is no injectable safety database.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
AHK-Cu is not FDA-approved for hair loss. No injectable safety or efficacy data exists; meaningful evidence is for topical formulations only.
Consult a board-certified dermatologist before starting any hair-loss protocol. Persistent shedding, patchy loss, or scalp inflammation needs in-person assessment, not a topical experiment.